Role of proinflammatory cytokines in cisplatin-induced vestibular hair cell damage

Head and Neck

Volumn 30, Issue 11, 2008, Pages 1445-1456

  Kim, Hyung Jin ^a   So, Hong Seob ^a   Lee, Jeong Han ^a   Park, Channy ^a   Lee, Jin Bin ^a   Youn, Myung Ja ^a   Kim, Se Jin ^a   Yang, Sei Hoon ^a   Lee, Kang Min ^b   Kwon, Kang Beom ^c   Park, Byung Hyun ^b   Park, Raekil ^a  

^a Wonkwang University   (South Korea)

^b Chonbuk National University   (South Korea)

^c Wonkwang University   (South Korea)

Author keywords

Cisplatin; MAP kinase; NF B; Proinflammatory cytokine; Vestibulotoxicity

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL DEATH; CONTROLLED STUDY; CRISTAE AMPULLAE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVATION; EPITHELIUM CELL; FEMALE; HAIR CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TEMPORAL BONE; UTRICLE; VESTIBULAR DISORDER; VESTIBULAR LABYRINTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CISPLATIN; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HAIR CELLS, VESTIBULAR; HEARING LOSS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; NF-KAPPA B;

EID: 55549146143     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20892     Document Type: Article

References (66)

1. Fram RJ. Cisplatin and platinum analogues: recent advances. Curr Opin Oncol 1992;4:1073-1079.
2. Black FO, Myers EN, Schramm VL, et al. Cisplatin vestibular ototoxicity: preliminary report. Laryngoscope 1982;92:1363-1368.
3. Hartwig S, Pettersson U, Stahle J. cis-Diamminedichloroplatinum: a cytostatic with an ototoxic effect. ORL J Otorhinolaryngol Relat Spec 1983;45:257-261.
4. Kitsigianis GA, O'Leary DP, Davis LL. Vestibular autorotation testing of cisplatin chemotherapy patients. Adv Otorhinolaryngol 1988;42:250-253.
5. Kitsigianis GA, O'Leary DP, Davis LL. Active head-movement analysis of cisplatin-induced vestibulotoxicity. Otolaryngol Head Neck Surg 1988;98:82-87.
6. Kobayashi H, Ohashi N, Watanabe Y, Mizukoshi K. Clinical features of cisplatin vestibulotoxicity and hearing loss. ORL J Otorhinolaryngol Relat Spec 1987;49:67-72.
7. Schaefer SD, Wright CG, Post JD, Frenkel EP. Cis-platinum vestibular toxicity. Cancer 1981;47:857-859.
8. Sergi B, Ferraresi A, Troiani D, Paludetti G, Fetoni AR. Cisplatin ototoxicity in the guinea pig: vestibular and cochlear damage. Hear Res 2003;182:56-64.
9. Sergi B, Fetoni AR, Ferraresi A, et al. The role of antioxidants in protection from ototoxic drugs. Acta Otolaryngol 2004(Suppl 552):42-45.
10. Schweitzer VG, Rarey KE, Dolan DF, Abrams GE, Sheridan C. Vestibular morphological analysis of the effects of cisplatin vs. platinum analogs, CBDCA (JM-8) and CHIP (JM-9). Laryngoscope 1986;96(9 Part 1):959-974.
11. Wright CG, Schaefer SD. Inner ear histopathology in patients treated with cis-platinum. Laryngoscope 1982; 92:1408-1413.
12. Nakayama M. Cisplatin induced vestibular damage [in Japanese]. Nippon Jibiinkoka Gakkai Kaiho 1992;95:81-94.
13. Nakayama M, Riggs LC, Matz GJ. Quantitative study of vestibulotoxicity induced by gentamicin or cisplatin in the guinea pig. Laryngoscope 1996;106(2 Part 1):162-167.
14. Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA, Haskins JR. Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int 1995;48:761-770.
15. Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986;8:368-379.
16. Sugiyama S, Hayakawa M, Kato T, Hanaki Y, Shimizu K, Ozawa T. Adverse effects of anti-tumor drug, cisplatin, on rat kidney mitochondria: disturbances in glutathione peroxidase activity. Biochem Biophys Res Commun 1989;159:1121-1127.
17. Matsushima H, Yonemura K, Ohishi K, Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med 1998;131:518-526.
18. Kaushal GP, Kaushal V, Hong X, Shah SV. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int 2001; 60:1726-1736.
19. Rybak LP, Whitworth C, Somani S. Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope 1999;109:1740-1744.
20. Harris JP. Immunology of the inner ear: evidence of local antibody production. Ann Otol Rhinol Laryngol 1984; 93(2 Part 1):157-162.
21. Satoh H, Firestein GS, Billings PB, Harris JP, Keithley EM. Proinflammatory cytokine expression in the endolymphatic sac during inner ear inflammation. J Assoc Res Otolaryngol 2003;4:139-147.
22. McCabe BF. Autoimmune sensorineural hearing loss. 1979. Ann Otol Rhinol Laryngol 2004;113:526-530.
23. Rahman MU, Poe DS, Choi HK. Autoimmune vestibulocochlear disorders. Curr Opin Rheumatol 2001;13:184-189.
24. Kanzaki J, Ouchi T. Steroid-responsive bilateral sensorineural hearing loss and immune complexes. Arch Otorhinolaryngol 1981;230:5-9.
25. So H, Kim H, Lee JH, et al. Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-κB. J Assoc Res Otolaryngol 2007;8:338-355.
26. Guha M, O'Connell MA, Pawlinski R, et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001;98:1429-1439.
27. Shen J, Sakaida I, Uchida K, Terai S, Okita K. Leptin enhances TNF-α production via p38 and JNK MAPK in LPS-stimulated Kupffer cells. Life Sci 2005;77:1502-1515.
28. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004;23:2838-2849.
29. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-260.
30. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999;79:143-180.
31. Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol 2004;287:F543-F549.
32. Mansouri A, Ridgway LD, Korapati AL, et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003;278:19245-19256.
33. Lawlor P, Marcotti W, Rivolta MN, Kros CJ, Holley MC. Differentiation of mammalian vestibular hair cells from conditionally immortal, postnatal supporting cells. J Neurosci 1999;19:9445-9558.
34. Rivolta MN, Holley MC. Asymmetric segregation of mitochondria and mortalin correlates with the multi-lineage potential of inner ear sensory cell progenitors in vitro. Brain Res Dev Brain Res 2002;133:49-56.
35. So H, Rho J, Jeong D, et al. Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor osteoclast-associated receptor gene expression. J Biol Chem 2003;278:24209-24216.
36. Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-683.
37. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
38. Abraham E. Nuclear factor-kappaB and its role in sepsis-associated organ failure. J Infect Dis 2003;187(Suppl 2):S364-S369.
39. Ma C, Billings P, Harris JP, Keithley EM. Characterization of an experimentally induced inner ear immune response. Laryngoscope 2000;110(3 Part 1):451-456.
40. Ryan AF, Harris JP, Keithley EM. Immune-mediated hearing loss: basic mechanisms and options for therapy. Acta Otolaryngol 2002(Suppl 548):38-43.
41. Stone JH, Francis HW. Immune-mediated inner ear disease. Curr Opin Rheumatol 2000;12:32-40.
42. Humes HD. Insights into ototoxicity. Analogies to nephrotoxicity. Ann N Y Acad Sci 1999;884:15-18.
43. Feghali JG, Liu W, Van De Water TR. L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope 2001;111:1147-1155.
44. Huang T, Cheng AG, Stupak H, et al. Oxidative stress-induced apoptosis of cochlear sensory cells: otoprotective strategies. Int J Dev Neurosci 2000;18:259-270.
45. Kopke RD, Liu W, Gabaizadeh R, et al. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol 1997;18:559-571.
46. Watanabe KC, Jinnouchi K, Hess A, Michel O, Baba S, Yagi T. Carboplatin induces less apoptosis in the cochlea of guinea pigs than cisplatin. Chemotherapy 2002;48:82-87.
47. Alam SA, Ikeda K, Oshima T, et al. Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea. Hear Res 2000;141:28-38.
48. Kartalou M, Essigmann JM. Recognition of cisplatin adducts by cellular proteins. Mutat Res 2001;478:1-21.
49. Kharbanda S, Pandey P, Yamauchi T, et al. Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage. Mol Cell Biol 2000;20:4979-4989.
50. Evans P, Halliwell B. Free radicals and hearing. Cause, consequence, and criteria. Ann N Y Acad Sci 1999;884:19-40.
51. Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 2001;12:2683-2690.
52. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000; 57:1229-1235.
53. Brady HR, Kone BC, Stromski ME, Zeidel ML, Giebisch G, Gullans SR. Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules. Am J Physiol 1990;258(5 Pt 2):F1181-7.
54. 2+-ATPase with the reversal of cisplatin ototoxicity induced by D-methionine in guinea pigs. Hear Res 2005;205:102-109.
55. Cheng PW, Liu SH, Young YH, Lin-Shiau SY. D-Methionine attenuated cisplatin-induced vestibulotoxicity through altering ATPase activities and oxidative stress in guinea pigs. Toxicol Appl Pharmacol 2006;215:228-236.
56. Watanabe K, Yagi T. Expression of myeloperoxidase in the inner ear of cisplatin-treated guinea pigs. Anticancer Drugs 2000;11:727-730.
57. Watanabe K, Hess A, Michel O, Yagi T. Nitric oxide synthase inhibitor reduces the apoptotic change in the cisplatin-treated cochlea of guinea pigs. Anticancer Drugs 2000;11:731-735.
58. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003;14:193-209.
59. Suzuki M, Tetsuka T, Yoshida S, et al. The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-α- or IL-1β-stimulated rheumatoid synovial fibroblasts. FEBS Lett 2000;465:23-27.
60. Wang L, Walia B, Evans J, Gewirtz AT, Merlin D, Sitaraman SV. IL-6 induces NF-kappa B activation in the intestinal epithelia. J Immunol 2003;171:3194-3201.
61. Tomiyama S, Harris JP. The endolymphatic sac: its importance in inner ear immune responses. Laryngoscope 1986;96:685-691.
62. Harris JP, Fukuda S, Keithley EM. Spiral modiolar vein: its importance in inner ear inflammation. Acta Otolaryngol 1990;110:357-365.
63. Yoshida K, Ichimiya I, Suzuki M, Mogi G. Effect of proinflammatory cytokines on cultured spiral ligament fibrocytes. Hear Res 1999;137:155-159.
64. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74: 49-139.
65. Hsu HY, Wen MH. Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J Biol Chem 2002;277: 22131-22139.
66. Shi L, Kishore R, McMullen MR, Nagy LE. Lipopolysaccharide stimulation of ERK1/2 increases TNF-α production via Egr-1. Am J Physiol Cell Physiol 2002;282: C1205-C1211.